Important safety considerations from the SmPC include monitoring for gallbladder disease and diabetic retinopathy complications
Other more serious side effects include: Chest pain High blood pressure Irregular heartbeats Circulation problems Heart attack, stroke, sudden death (particularly in people with pre-existing heart conditions) Mental health issues: delusions, paranoia, aggression, mania, depression, severe anxiety Always report any side effects to your clinician and go to emergency services when needed
News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
It acts at the neuromuscular junction to inhibit the release of acetylcholine, the neurotransmitter responsible for initiating muscle contraction
Has anyone tried GHRP-2 or 6
